American Heart Journal
Volume 154, Issue 4 , Pages 637-644 , October 2007

Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN)

  • Gregg C. Fonarow, MD

      Affiliations

    • Ahmanson-UCLA Cardiomyopathy Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Gregg C. Fonarow, MD, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, 10833 LeConte Avenue, Room 47-123 CHS, Los Angeles, CA 90095-1679.
    • ,
  • Mary Ann Lukas, MD

      Affiliations

    • Cardiovascular and Metabolic Medicine Development Center, GlaxoSmithKline, Philadelphia, PA
    • ,
  • Michele Robertson, BSc

      Affiliations

    • Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
    • ,
  • Wilson S. Colucci, MD

      Affiliations

    • Section of Cardiology, Department of Medicine, Boston University School of Medicine, Boston, MA
    • ,
  • Henry J. Dargie, MD

      Affiliations

    • Department of Cardiology, Western Infirmary, Glasgow, United Kingdom

Received 16 April 2007 ,Accepted 10 June 2007.

References 

  1. Rasamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics---2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e71
  2. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670–1676
  3. Cleland JG, Torabi A, Khan NK. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart. 2005;91(Suppl 2):ii7–ii13
  4. Velazquez EJ, Francis GS, Armstrong PW, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J. 2004;25:1911–1919
  5. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–2588
  6. CAPRICORN Investigators . Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  7. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425–431
  8. Sackner-Bernstein JD. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. Rev Cardiovasc Med. 2003;4(Suppl 3):S25–S29
  9. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation. 2004;110:588–636
  10. Wu AH, Parsons L, Every NR, et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. J Am Coll Cardiol. 2002;40:1389–1394
  11. Spencer FA, Meyer TE, Gore JM, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure. Circulation. 2002;105:2605–2610
  12. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ. 1999;318:1730–1737
  13. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66
  14. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J. 1985;6:199–226
  15. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983;67:I26–I32
  16. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J. 1987;8:1056–1064
  17. COMMIT Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–1632
  18. Sabatine MS. Something old, something new: beta blockers and clopidogrel in acute myocardial infarction. Lancet. 2005;366:1587–1589
  19. Fonarow GC. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J. 2005;149:984–993
  20. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712–718
  21. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321

PII: S0002-8703(07)00494-2

doi: 10.1016/j.ahj.2007.06.002

American Heart Journal
Volume 154, Issue 4 , Pages 637-644 , October 2007

Article Tools

* Image Usage & Resolution